Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia

Table 3 Univariate and multivariate analyses for relapse, OS, DFS, and GRFS

Risk factors	Relapse		OS		DFS		GRFS
Risk factors	Univariate	Multivariate (P (HR, 95% CI))	Univariate	Multivariate (P (HR, 95% CI))	Univariate	Multivariate (P (HR, 95% CI))	Univariate	Multivariate (P (HR, 95% CI))
Female vs male	NS	NS	NS	NS	NS	NS	NS	NS
Patient age, ≥33 vs <33 years	NS	NS	NS	NS	NS	NS	NS	P = 0.039 (2.02, 1.07–3.8)
ALL vs AML	NS	NS	NS	NS	NS	NS	NS	NS
High risk vs standard risk	NS	NS	NS	NS	P = 0.03	P = 0.028 (2.31, 1.09–4.87)	NS	P = 0.018 (2.14, 1.14–4.02)
G-PBSC vs G-BM	NS	NS	NS	NS	NS	NS	P = 0.03	P = 0.071 (1.82, 0.95–3.49)
CD3⁺ T, ≥166 × 10⁶ vs <166 × 10⁶ cells/kg	NS	NS	NS	NS	NS	NS	NS	NS
Treg, <5.2 × 10⁶ vs ≥5.2 × 10⁶ cells/kg	NS	NS	NS	NS	NS	NS	NS	NS
MDSCs, <3.65 × 10⁶ vs ≥3.65 × 10⁶ cells/kg	NS	NS	NS	NS	NS	NS	P < 0.001	P < 0.001 (3.49,1.77–6.90)

OS overall survival, DFS disease-free survival, GRFS GVHD-free/relapse-free survival, ALL acute lymphoblastic leukemia, AML acute myelogenous leukemia, TNC total nucleated cells

ISSN: 1756-8722